| Objective:through retrospective analysis of clinical patients,to obtain historical examination data,and to systematically explore the hormone receptor positive,The effect of HR+on the change of the size of hepatic hemangioma(HH)in breast cancer patients after the comprehensive treatment of anti malignant tumor.It was found that the treatment of breast cancer can effectively inhibit the growth of hepatic hemangioma at the same time.Methods:the data of breast cancer patients from January 1,2013 to December 3 1,2018 in the breast cancer center of Yunnan cancer hospital were collected,and the first time of abdominal color Doppler ultrasound(ADUS)+contrast enhanced was selected A total of 323 breast cancer patients with hemangioma of the liver were diagnosed by ultrasound(CEUS)and at least once upper abdominal CT.According to the expression of hormone receptor,the patients in the group were divided into two groups:HR+group and HR-group.The basic information of each patient before hospitalization and the treatment received during hospitalization were counted,including breast cancer stage,axillary lymph node status,chemotherapy plan,chemotherapy times,endocrine drug use,etc.Follow up time:6-78 months from the first diagnosis of hemangioma to July 1,2019.The follow-up was mainly to evaluate the location,number and size of HR + and HR breast cancer patients’ hemangiomas in different stages of treatment by B-mode ultrasound and CT imaging.The data were statistically analyzed to compare the changes of liver hemangiomas in HR+and HR group of breast cancer,and the corresponding subgroups of patients receiving chemotherapy and endocrine treatment were analyzed and compared.Results:there were 323 breast cancer patients with hemangioma of liver,238(73.7%)with HR and 85(26.3%)with HR.Compared with breast cancer HR group,the longest diameter and(long diameter x short diameter)of hepatic hemangioma in HR+ group were statistically analyzed,among which(long diameter x short diameter)T12 time points were compared between the two groups,P<0.05,there was no statistical difference in the longest diameter,P=0.556;the size of hepatic hemangioma was not related to axillary lymph node metastasis of breast cancer,P=0.804,P=0.795;during chemotherapy,patients with hepatic hemangioma were compared After chemotherapy,there was no significant change in hemangioma of the liver during chemotherapy,and the hemangioma of the liver increased after chemotherapy.There was no difference in the overall comparison,but the p value at multiple time points was less than 0.01,which was statistically significant.There was no difference between tamoxifen(TAM)group and other combined or sequential treatment groups,P=0.076,P=0.114;only aromatase inhibitor inhibitor group was used The p value of T1 time point in AI group was less than 0.05,which was statistically significant.Conclusion:during chemotherapy and endocrinotherapy for breast cancer patients with hemangioma of the liver,it is found that the size of hemangioma of the liver has changed in some patients,and new hemangioma of the liver appears in some patients,and the cause is still unclear.Chemotherapy and endocrine therapy have influence on the size of hemangioma in breast cancer.During chemotherapy,there was no significant growth of hemangioma of the liver,and if no further endocrine therapy was given after chemotherapy,it could still continue to grow.Tamoxifen has no significant effect on the size of hemangioma of the liver.Postmenopausal women can inhibit the growth and reduce the size of hemangioma of the liver after using aromatase inhibitors.Other endocrine therapies,such as ovarian function inhibitors(OFS)+tamoxifen,ovarian function inhibitors+aromatase inhibitors,tamoxifen sequential aromatase inhibitors,have not been observed in this study. |
PDF Full Text Request